Deciphering the AMT Designation Program

As biopharma moves beyond traditional batch processing, industry leaders evaluate how the FDA’s Advanced Manufacturing Technology designation program is reshaping process innovation, risk mitigation, and strategic CDMO partnerships.

When the FDA finalized its Advanced Manufacturing Technology (AMT) designation program framework (1), it marked a pivotal regulatory commitment to modernizing pharmaceutical production. However, translating regulatory incentives into operational reality presents a complex balancing act between adoption and upfront costs and risks.

To find out more about the AMT designation program and its impact on the bio/pharma industry, The Pharma Navigator convened a panel of technical, operational, and regulatory experts. The panel comprised Veerendra Kumar Reddy, PhD, Head of Manufacturing Operations, India Site, Enzene; Alexa Crăciunescu, Board and Founding Member, and David Mix, Programme Director, both from Act for Hope; and Alexander Seyf, CEO of Autolomous.

Click above to view the video panel discussion or read on for more…

Defining Advanced Manufacturing Technology

TPN: From an operational perspective, how would you define what truly qualifies as an advanced manufacturing technology?

Reddy (Enzene): From an operational point of view, technology qualifies as advanced if it achieves three main goals: innovation beyond traditional fed-batch processes, improved reliability and robustness, and strengthened supply chain resilience.

For example, continuous manufacturing with perfusion technology increases productivity five to ten times compared to traditional fed batches while reducing variability to maintain steady product quality. Similarly, advanced Process Analytical Technology (PAT) creates online monitoring so we can control the process in real time and ensure product quality. In short, if a technology improves reproducibility, reduces cycle time, increases productivity, and makes the supply chain more dependable, it qualifies as advanced.

Crăciunescu (Act for Hope): Given my background in compliance and digitization, I evaluate it by anything that removes risk and increases certainty and safety. It is not just about having something fancy or novel, especially when dealing with patients who cannot provide optimal starting materials due to health conditions. You cannot assume any risk. Anything that decreases that risk is operationally novel and worth pursuing.

Mix (Act for Hope): Actual utility and adoption are still emerging. Engaging these regulatory frameworks requires significant capacity, making it a cost-benefit analysis for companies. That is why there is such an emphasis on technology and data sharing.

I view progress within these ecosystems like constellations—you assemble working groups comprising technology experts and manufacturing engineers, held together by technology. Platforms like the AMT program provide utility, but for smaller players and startups, we must ensure they have the opportunity to bring innovation to the marketplace so everyone is brought along.

Seyf (Autolomous): Innovation in life happens by agreeing to do things differently. This designation encourages the industry to stop repeating the same methods used for past decades.

It reminds me of the open-source movement in software during the 1990s. Back then, closed ecosystems limited rapid movement. Open source created industries and accelerated innovation because it allowed people to collaborate, look at problems from different perspectives, and build the right solutions together.

However, data remains a challenge. Pen and paper limit what you can achieve, whereas digital systems embrace collaboration, learning, and dynamic decision-making. The industry is shifting from asking if they should digitize to when, which is a vital maturity step for adopting this designation.

Caution versus Speed in Adoption

TPN: Now that the program has been active for some time, what shifts are you observing across the industry? Are drug sponsors and CDMOs actively seeking AMT designations or is adoption taking a more cautious path?

Seyf (Autolomous): We operate in a very fragile industry where mistakes have profound and lasting impacts. We must remain cautious, but a little bit of daring — supported by digital guardrails — would not harm. Digital guardrails offer stronger protection than physical ones.

To dare, we must break through silos and collaborate. Consider how the world addressed the ozone layer in the 1990s: nations and companies collaborated, instituted restrictions, innovated, and solved a global problem within two decades. The biopharma industry can achieve similar breakthroughs if we work together.

Mix (Act for Hope): Scale risk is a primary concern. As engineering solutions scale, we must evaluate if they are truly becoming more efficient, effective, and cost-conscious. Exploring these opportunities through collaborative working groups and think tanks helps identify the best paths forward.

Crăciunescu (Act for Hope): CDMOs and technology providers often start on the equipment side before expanding into broader manufacturing services, largely driven by risk management. The industry uses standardized equipment in cleanrooms because it is proven and reliable. While I want us to be more innovative, changes must happen in a way where everyone feels comfortable, as market and public perception react sharply to failure. We need open forums to discuss ideas before making public commitments.

Reddy (Enzene): We are seeing a gradual shift, with continuous manufacturing and PAT leading the way. However, adoption speed varies. For startups, implementing AMT is straightforward because they can build their process and infrastructure around advanced technology from scratch. For established companies, implementing AMT is complex; it requires re-engineering legacy systems, retraining personnel, and restructuring supply chains built over decades, which creates inertia. Nonetheless, momentum across the broader market is building.

High-Traction Application Areas

TPN: Are there specific application areas, such as continuous biomanufacturing, end-to-end PAT integration, or modular platforms, that are gaining more traction under the AMT banner?

Mix (Act for Hope): You have to consider this against the backdrop of complex molecules and smaller target patient populations. With advancements in AI and engineering, we must determine which specific technologies to prioritize within the broader systems framework.

Crăciunescu (Act for Hope): Technologies that make manufacturing as closed and automated as possible offer immediate value. Being able to run multiple closed systems in parallel within the same space transforms efficiency and scale-up.

Additionally, rapid inline testing and characterization show immense promise. While PAT integration is harder to apply in cell and gene therapy (CGT) due to high inherent variability, modular components and inline testing provide clearer entry points. Regulatory shifts toward decentralized manufacturing, such as in the UK, will also benefit significantly from modular AMT designations.

Reddy (Enzene): Continuous manufacturing is at the forefront. Sponsors and CDMOs are actively investing in perfusion and continuous downstream processing because they deliver higher volumetric productivity, better yield, shorter cycle times, and more resilient supply chains.

PAT is critical here because real-time monitoring controls the process, reduces variability, and builds regulatory confidence. Portable and modular platforms are also gaining traction due to their rapid scale-up potential.

Seyf (Autolomous): When pioneers secure recognition for new systems, it creates a ripple effect across the industry. As adoption spreads, standardization becomes essential. Standardization benefits everyone — including regulators.

Regulatory bodies encourage industry players to innovate boldly and establish standards collaboratively, which minimizes downstream compliance risks.

Balancing Regulatory Benefits Against Costs

TPN: Early interaction with the FDA and streamlined reviews are major incentives. In practice, how do these regulatory benefits balance against upfront CapEx, validation workloads, and platform maturity requirements?

Seyf (Autolomous): Early interaction helps, but it does not solve every challenge. Adhering to quality requirements remains mandatory. However, collecting data digitally creates provenance, auditability, and certainty that streamline FDA reviews, cutting down review timelines significantly.

Modern instrumentation must be built digitally. The next step for the industry is to move beyond in-house data collection to active data sharing and collaboration. True innovation comes from working together across sectors rather than locking ourselves away in isolation.

Crăciunescu (Act for Hope): Early regulatory reviews are critical, but smaller players often cannot afford the upfront investment. It often makes the most sense for technology and hardware developers to secure designations for modular products that can be deployed repeatedly.

Startups can then leverage those recognized platforms and focus their capital on their proprietary differentiators. This cost dynamic naturally drives deeper collaborations between CDMOs, hardware developers, and emerging biopharma companies.

Mix (Act for Hope): The AMT pathway provides a mechanism for knowledge sharing regarding supply chain improvements, supervisory controls, and data acquisition. We should not reinvent the wheel every time a new technology emerges. Supporting emerging developers through cross-sector collaboration accelerates market access and lowers costs while maintaining rigorous standards.

Reddy (Enzene): CapEx is a major hurdle, but continuous manufacturing offers a distinct advantage: a significantly smaller footprint. For example, producing 30 kg of material conventionally might require a 10,000-liter bioreactor facility with extensive supporting equipment and high CapEx. Continuous manufacturing can achieve that same output with a 1,000-liter setup due to high volumetric productivity.

Conversely, validation workloads are heavier for AMT because it demands extensive compatibility studies, robust lifecycle management, and proven platform maturity to satisfy regulatory standards.

Future Outlook

TPN: Looking ahead over the next three to five years, how do you expect the AMT program to influence how biopharma companies build out manufacturing networks and CDMO partnerships?

Reddy (Enzene): Over the next three to five years, the AMT program will reshape manufacturing strategies. For CDMOs, holding AMT-designated platforms will become a key strategic differentiator. Sponsors will prioritize partners who offer continuous manufacturing and real-time PAT capabilities. We will also see evolving commercial models, including joint risk- and cost-sharing investments between CDMOs and sponsors in advanced platforms.

Mix (Act for Hope): Demonstrated performance and regulatory track records will dictate who leads the space. Technology platforms will serve as the connective tissue for data sharing and resilient manufacturing networks.

Our ultimate goal is to increase access for patients and reduce treatment costs. The AMT program offers one of several key pathways to build collective capacity across both small and large organizations.

Crăciunescu (Act for Hope): I expect this momentum to drive formal standardization around data structuring and data sharing. This will encourage new cross-geography alliances and specialized partnerships delivering end-to-end solutions, ultimately expanding global patient access to advanced therapies.

Seyf (Autolomous): The regulatory framework is set, but its ultimate value depends on industry execution. Companies must adopt a digital-first mindset to maximize the value of AI and advanced manufacturing frameworks.

We must shift away from the old mindset of trying to build everything in-house. If another organization has developed a proven, reliable solution, collaborate with them rather than wasting time reinventing the wheel. Combining best-in-class specialized capabilities is the fastest way to deliver complete, effective solutions to patients.

Reference

1. FDA. Advanced Manufacturing Technologies Designation Program. Guidance Document, December 2024.

Music: 'Frisbee' by Tatami on #Uppbeat https://uppbeat.io/c/tatami
License code: 4ACTDH9DBJJIUX6Y

Image Credit: © Celt Studio - stock.adobe.com